BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20138939)

  • 1. RNA interference by nanofiber-based siRNA delivery system.
    Cao H; Jiang X; Chai C; Chew SY
    J Control Release; 2010 Jun; 144(2):203-12. PubMed ID: 20138939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanofiber-mediated controlled release of siRNA complexes for long term gene-silencing applications.
    Rujitanaroj PO; Wang YC; Wang J; Chew SY
    Biomaterials; 2011 Sep; 32(25):5915-23. PubMed ID: 21596430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localized and sustained delivery of silencing RNA from macroscopic biopolymer hydrogels.
    Krebs MD; Jeon O; Alsberg E
    J Am Chem Soc; 2009 Jul; 131(26):9204-6. PubMed ID: 19530653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained delivery of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene silencing.
    Pinese C; Lin J; Milbreta U; Li M; Wang Y; Leong KW; Chew SY
    Acta Biomater; 2018 Aug; 76():164-177. PubMed ID: 29890267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic and efficacy analysis of RNA interference in stably and transiently expressing cell lines.
    Grayson AC; Ma J; Putnam D
    Mol Pharm; 2006; 3(5):601-13. PubMed ID: 17009859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery.
    Wang XL; Xu R; Lu ZR
    J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
    Takahashi Y; Nishikawa M; Takakura Y
    Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts.
    Yoshizawa T; Hattori Y; Hakoshima M; Koga K; Maitani Y
    Eur J Pharm Biopharm; 2008 Nov; 70(3):718-25. PubMed ID: 18647651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
    Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
    J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene delivery in three-dimensional cell cultures by superparamagnetic nanoparticles.
    Zhang H; Lee MY; Hogg MG; Dordick JS; Sharfstein ST
    ACS Nano; 2010 Aug; 4(8):4733-43. PubMed ID: 20731451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An intracellular delivery method for siRNA by an arginine-rich peptide.
    Wang YH; Hou YW; Lee HJ
    J Biochem Biophys Methods; 2007 Jun; 70(4):579-86. PubMed ID: 17320189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A peptidomimetic siRNA transfection reagent for highly effective gene silencing.
    Utku Y; Dehan E; Ouerfelli O; Piano F; Zuckermann RN; Pagano M; Kirshenbaum K
    Mol Biosyst; 2006 Jun; 2(6-7):312-7. PubMed ID: 16880950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain.
    Kim ID; Lim CM; Kim JB; Nam HY; Nam K; Kim SW; Park JS; Lee JK
    J Control Release; 2010 Mar; 142(3):422-30. PubMed ID: 19944723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.
    Tagalakis AD; He L; Saraiva L; Gustafsson KT; Hart SL
    Biomaterials; 2011 Sep; 32(26):6302-15. PubMed ID: 21624650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel nonviral gene silencing system that is effective both in vitro and in vivo by using a star-shaped block copolymer (star vector).
    Mori T; Ishikawa A; Nemoto Y; Kambe N; Sakamoto M; Nakayama Y
    Bioconjug Chem; 2009 Jun; 20(6):1262-9. PubMed ID: 19456093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
    Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
    Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.
    Kim SW; Kim NY; Choi YB; Park SH; Yang JM; Shin S
    J Control Release; 2010 May; 143(3):335-43. PubMed ID: 20079391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
    Tan WB; Jiang S; Zhang Y
    Biomaterials; 2007 Mar; 28(8):1565-71. PubMed ID: 17161865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.